Mapping cardiac remodeling in chronic kidney disease

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Molecular Biology

Background:

• Advanced chronic kidney disease (CKD) is associated with high mortality from sudden cardiac death and heart failure.
• The molecular and cellular mechanisms underlying cardiac remodeling in CKD remain poorly understood.
• Understanding these mechanisms is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To dissect the molecular and cellular mechanisms of cardiac remodeling in CKD using an unbiased approach.
• To identify key molecular players and cellular pathways involved in CKD-associated cardiac changes.
• To explore potential therapeutic targets for mitigating cardiac remodeling in CKD.

Main Methods:

• Single-nuclear RNA sequencing was performed on left ventricular tissue from two mouse models of CKD.
• Integrated analysis of cellular responses to uremic toxins was conducted.
• In vitro and in vivo experiments were used to validate findings, including TNFα inhibition.

Main Results:

• CKD induced a hypertrophic response in cardiomyocytes, characterized by stress signaling and metabolic alterations, driven by soluble uremic factors.
• Fibroblast to myofibroblast differentiation and significant changes in cardiac vasculature, indicating inflammation and dysfunction, were observed.
• Endothelin-1 and methylglyoxal were implicated in capillary dysfunction, while TNFα was identified as a driver of cardiomyocyte hypertrophy, which was validated and ameliorated by TNFα inhibition.

Conclusions:

• Uremic toxins significantly contribute to cardiac remodeling in CKD through distinct cellular pathways.
• TNFα plays a critical role in driving cardiomyocyte hypertrophy in the context of CKD.
• Targeting specific uremic toxins, such as TNFα, represents a promising therapeutic avenue for ameliorating cardiac remodeling and improving outcomes in CKD patients.